Medsafe has approved weight loss drug Wegovy for use in New Zealand.
Wegovy, a semiglutide prescription injection developed by Novo Nordisk Pharmaceuticals, acts to regulate appetite by increasing feelings of fullness and reducing cravings for food.
Medsafe, which is New Zealand’s regulatory for medicines, previously approved the use of Ozempic for the purpose of treating type 2 diabetes.
“Wegovy has been approved by Medsafe for use in weight loss,” a spokesperson said.
“The decision to supply Wegovy in New Zealand sits with the company, Novo Nordisk Pharmaceuticals.”
A Novo Nordisk spokesperson said the decision by MedSafe was “great news”.
Approval for the popular medication said to be a “game changer” for many New Zealanders. (Source: 1News)
“Wegovy is not yet available in New Zealand. Novo Nordisk is exploring options to provide access to Wegovy for people living with obesity and overweight in New Zealand as soon as possible.”
The medicine has been allowed for use as an adjunct to a reduced-calorie diet and increased physical activity for weight loss in adults with a BMI classing them as obese, or overweight in the presence of at least one weight-related comorbidity.
It could also be used by some young people aged over 12 who met certain criteria.
Associate Health Minister David Seymour said the approval of the weight loss drug was a “game changer” for many New Zealanders.
“Now it’s legal in New Zealand, I hope Novo Nordisk will decide to make supply available to New Zealanders.”